Singapore:Layout 1 14/1/10 20:19 Page 86
Regional Focus
Millipore set up its first regional training centre for
biopharmaceutical manufacturing, in response to
the growing base of biologics plants in Singapore.
Building on its strong track record for chemical-
based pharmaceutical and biologics manufactur-
ing, Singapore is building up capabilities in process
development and green manufacturing. In 2009,
Bioprocessing Technology Institute partnered
GlaxoSmithKline Biologicals for vaccine and
process development. GlaxoSmithKline also
announced a S$50 million endowment fund, joint-
ly launched with the EDB, to fund graduate studies
in green manufacturing and public health policy.
Forging long-standing partnerships
Singapore is committed to be in time for the future
and is committed to partnering companies to co-
create solutions to address unmet healthcare needs
in Asia and the industry’s challenges.
Companies’ corporate labs are a71 Growing base of supporting industry players to Key highlights in 2009 include Lonza’s foray
co-located with public-sector
support pharmaceutical and biotechnology compa- into cell therapy after investing in the first biolog-
research institutes in the
nies’ engineering and infrastructural needs to imple- ics plants in Singapore; Baxter’s expansion from 30
2.4-million sq ft Biopolis
campus that advances science
ment cutting-edge manufacturing technologies. years of medical device and implantable manufac-
and human healthcare via
turing into biopharmaceutical manufacturing;
cross-disciplinary, public- Singapore is strengthening its position as Asia’s GSK’s partnership with EDB in launching the S$50
private collaborations
leading site for biopharmaceutical manufacturing. million endowment fund for graduate studies in
In 2009, leading companies located their first-in- green manufacturing and public health policy, on
Asia facilities in Singapore – GlaxoSmithKline the occasion of its 50th anniversary of doing busi-
opened its vaccine plant that will produce purified ness in Singapore.
bulk polysaccharides and conjugates which are used As global pharmaceutical and biotechnology
to manufacture GSK’s new pneumococcal conjugate companies seek to locate their key business func-
vaccine, meningitis and other new innovative vac- tions and decision-makers closer to the fast-grow-
cines; Baxter commenced construction for its ing Asian markets, Singapore presents a strategic
Advate plant; Roche purchased Lonza’s mam- base as these companies’ home-base for the busi-
malian-cell facility to manufacture Avastin and offi- ness expansion and innovation in Asia. DDW
cially opened its microbial-cell facility to manufac-
ture Lucentis. Singapore also made headway in cell
therapy with Lonza’s first-in-Asia cell therapy plant.
Within five years since the first biologics
announcement, leading companies have invested Kian-Teik Beh is Director, Biomedical Sciences, of
about US$2 billion in six major plants. In 2009, The Singapore Economic Development Board.
ADVERTISEMENT INDEX
Biocius Life Sciences 25 HTStec Ltd 57 Quotient Bioresearch 59
BioFocus DPI plc 6 ID Business Solutions Ltd 20 Select Biosciences Ltd IBC
BioTek Instruments, Inc. 11 Life Technologies Corporation 15 Society of Biomolecular Sciences 79
BMG Labtech Gmbh 19 Millipore Corporation 26 Symyx Technologies, Inc. 32
Cambridge Healthtech Institute 47 Minitab, Inc. 40 Tecan Schweiz AG IFC-3
CISBIO International S.A 8 PerkinElmer Life & Analytical Sciences 52,73 Thermo Fisher Scientific OBC
ForteBio, Inc. 65 Promega Corporation 25
86 Drug Discovery World Winter 2009/10
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88